Table 1 Baseline variables of the included patients
From: Gender differences at presentation of idiopathic pulmonary fibrosis in Sweden
Baseline variables | Total |
|---|---|
IPF-patients (N = 348) | |
Incident / Prevalent (N, %) | 182 (52.3) / 166 (47.7) |
Gender (male /female) (N, %) | 250 (71.8) / 98 (28.1) |
Age (Median, range) | 72.0 (46–88) |
BMI (M ± SD) | 27.1 ± 4.2 |
Smoking habit (N = 348) | |
Never smoker (N, %) | 103 (29.6) |
Ex-smoker (N, %) | 222 (63.8) |
Packyear (M ± SD) (Ex-smoker, n = 160) | 23.0 ± 15.0 |
Smoker (N, %) | 12 (3.5) |
Missing info (N, %): | 11 (3.2) |
Lung function | |
FVC% (M ± SD) (N = 287) | 70.2 ± 15.6 |
FEV1% (M ± SD) (N = 307) | 76.1 ± 16.6 |
TLC% (M ± SD) (N = 193) | 63.9 ± 12.0 |
DLCO% (M ± SD) (N = 221) | 46.2 ± 13.9 |
6-WMT (N = 198) | |
6-WMD (M ± SD, m) | 422 ± 124 |
B-SpO2% (M ± SD, %) | 95.8 ± 2.3 |
L-SpO2% (M ± SD, %) | 86.1 ± 6.7 |
Comorbidity (N = 348) | |
Arterial hypertension (N, %) | 115 (33.0) |
Gastroesophageal reflux (N, %) | 113 (32.5) |
Other cardiovasculara (N, %) | 86 (24.7) |
Coronary heart disease (N, %) | 67 (19.3) |
Diabetes (N, %) | 52 (14.9) |
Cancer (N, %) | 33 (9.5) |
Thyroid diseasesb (N, %) | 22 (6.3) |
Sleep apnea (N, %) | 22 (6.3) |
Asthma (N, %) | 15 (4.3) |
COPD (N, %) | 10 (2.9) |
Osteoporosis (N, %) | 6 (1.7) |
K-BILD (N = 292) | 53.7 ± 10.7 |
Anti-fibrotic treatment (N, %) | 67 (19.3) |
Time from diagnosis to consent (median, Q1- Q3) (months) | 4 (Q1:0; Q3: 26) |